Many people suffer from elevated blood lipids for a long time, especially hypercholesterolemia. Cholesterol is an important component of blood lipids. Long-term elevation of blood lipids may lead to the formation of plaques in blood vessel walls and blockages. Blood vessels, some oral hypolipidemic drugs can effectively lower blood lipids, but some patients still cannot reduce blood lipids to a satisfactory level after taking them. “Blood lipid vaccine” helps these patients to further reduce blood lipids.
The so-called blood lipid vaccine is actually a biological preparation. It is an injection produced by small interfering RNA technology. The main target cells are liver cells that produce low-density lipoprotein cholesterol. The drug enters the corresponding site and shuts down the generation of PCSK9 from the source, thereby reducing the level of LDL-C (low-density lipoprotein cholesterol), and helping to improve the prognosis of patients with atherosclerosis and reduce the incidence of cardiovascular and cerebrovascular disease events , to achieve the purpose of reducing the mortality of such patients.
In 2020, this type of drug will be officially approved for marketing in Europe. Two to three injections can effectively reduce blood cholesterol levels. The representative drug inclisiran is priced at 18,000 yuan each, which is relatively high. .
